In CML and Ph+ ALL, treatment based exclusively on the inhibition of BCR-ABL kinase activity (e.g., imatinib and its analogs) will clearly not improve patient outcome if BCR-ABL–independent resistance occurs, and may select for resistant clones [23]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.